Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats

British Journal of Pharmacology

Volumn 164, Issue 5, 2011, Pages 1410-1420

  Liu, Wei Jing ^a   Jin, Heung Yong ^a   Lee, Kyung Ae ^a   Xie, Shu Hua ^a   Baek, Hong Sun ^a   Park, Tae Sun ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

apoptosis; cAMP; diabetic neuropathy; exendin 4; GLP 1 pathway

Indexed keywords

CASPASE 3; CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG TARGETING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; MYELINATED NERVE; NERVE DEGENERATION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE STUDY; RAT; SCHWANN CELL; STREPTOZOCIN DIABETES;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; MALE; NERVE FIBERS, MYELINATED; NEUROPROTECTIVE AGENTS; PEPTIDES; PERIPHERAL NERVOUS SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SCHWANN CELLS; SCIATIC NERVE; SKIN; STREPTOZOCIN; VENOMS;

EID: 80054051051     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01272.x     Document Type: Article

References (50)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Beiswenger KK, Calcutt NA, Mizisin AP, (2008). Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 110: 351-362.
3. Bosi E, (2010). Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab 95: 2607-2609.
4. Bunge RP, (1994). The role of the Schwann cell in trophic support and regeneration. J Neurol 242 (Suppl. 1): S19-S21. (Pubitemid 24367035)
5. Cui X, Lee SJ, Kim SZ, Kim SH, Cho KW, (2000). Effects of pituitary adenylate cyclase activating polypeptide27 on cyclic AMP efflux and atrial dynamics in perfused beating atria. Eur J Pharmacol 402: 129-137. (Pubitemid 30625319)
6. Drucker DJ, (2003). Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144: 5145-5148. (Pubitemid 37476039)
7. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al,. (2003). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9: 1173-1179. (Pubitemid 37173702)
8. Egan JM, Bulotta A, Hui H, Perfetti R, (2003). GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 19: 115-123. (Pubitemid 36417195)
9. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al,. (2003). Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26: 2370-2377. (Pubitemid 36993328)
10. Girach A, Vignati L, (2006). Diabetic microvascular complications-can the presence of one predict the development of another? J Diabetes Complications 20: 228-237. (Pubitemid 43949349)
11. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP, (1995). Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7: 2294-2300.
12. Hirai A, Yasuda H, Joko M, Maeda T, Kikkawa R, (2000). Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves. J Neurol Sci 172: 55-62. (Pubitemid 30006982)
13. Hoybergs YM, Biermans RL, Meert TF, (2008). The impact of bodyweight and body condition on behavioral testing for painful diabetic neuropathy in the streptozotocin rat model. Neurosci Lett 436: 13-18.
14. Ionescu-Tirgoviste C, Pruna S, Bajenaru O, Cheta D, Mincu I, (1987). The perception threshold to an electric stimulus deeply applied in the lower limbs in normal and diabetic subjects. Diabetes Res Clin Pract 3: 249-256. (Pubitemid 17137991)
15. Jakobsen J, (1979). Early and preventable changes of peripheral nerve structure and function in insulin-deficient diabetic rats. J Neurol Neurosurg Psychiatry 42: 509-518. (Pubitemid 9160947)
16. Jin HY, Liu WJ, Park JH, Baek HS, Park TS, (2009). Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 40: 536-544.
17. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, et al,. (2008). Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 48: 1389-1399.
18. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ, (2003). Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471-478. (Pubitemid 36043598)
19. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, et al,. (2009a). GLP-1 Receptor Stimulation Reduces Amyloid-beta Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. J Alzheimers Dis 19: 1205-1219.
20. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al,. (2009b). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 106: 1285-1290.
21. Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH, (2010). Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem 113: 1621-1631.
22. List JF, He H, Habener JF, (2006). Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Pept 134: 149-157.
23. Liu WJ, Jin HY, Park JH, Baek HS, Park TS, (2010). Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat. Eur J Pharmacol 637: 70-76.
24. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, et al,. (2006). Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30: 1332-1340. (Pubitemid 44306514)
25. Medori R, Autilio-Gambetti L, Monaco S, Gambetti P, (1985). Experimental diabetic neuropathy: impairment of slow transport with changes in axon cross-sectional area. Proc Natl Acad Sci USA 82: 7716-7720. (Pubitemid 16204419)
26. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, et al,. (2004). Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43. (Pubitemid 38180536)
27. O'Neill JH, Gilliatt RW, (1987). Adaptation of the myelin sheath during axonal atrophy. Acta Neuropathol 74: 62-66. (Pubitemid 17105419)
28. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, et al,. (2007). Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18: 1227-1238. (Pubitemid 46536909)
29. Park JK, Cui Y, Kim MK, Kim YG, Kim SH, Kim SZ, et al,. (2002). Effects of extracorporeal shock wave lithotripsy on plasma levels of nitric oxide and cyclic nucleotides in human subjects. J Urol 168: 38-42. (Pubitemid 34640780)
30. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al,. (2001). Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53: 260-267. (Pubitemid 33029654)
31. Perry T, Greig NH, (2003). The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 24: 377-383. (Pubitemid 37315530)
32. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH, (2002a). Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881-888. (Pubitemid 34920207)
33. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al,. (2002b). A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300: 958-966. (Pubitemid 34165002)
34. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al,. (2003). Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72: 603-612. (Pubitemid 36578646)
35. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al,. (2007). Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203: 293-301. (Pubitemid 46157226)
36. Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L, et al,. (2010). The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 33: 1294-1296.
37. Rother KI, Spain LM, Wesley RA, Digon BJ, 3rd, Baron A, Chen K, et al,. (2009). Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 32: 2251-2257.
38. Saito H, Kanje M, Dahlin LB, (2009). Delayed nerve repair increases number of caspase 3 stained Schwann cells. Neurosci Lett 456: 30-33.
39. Shindo H, Tawata M, Onaya T, (1993). Cyclic adenosine 3′,5′-monophosphate enhances sodium, potassium-adenosine triphosphatase activity in the sciatic nerve of streptozotocin-induced diabetic rats. Endocrinology 132: 510-516. (Pubitemid 23056100)
40. Suh KS, Oh SJ, Woo JT, Kim SW, Yang IM, Kim JW, et al,. (1999). Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats. Korean J Intern Med 14: 34-40.
41. Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS, (2005). Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res 37: 627-632. (Pubitemid 41597574)
42. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C, (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682. (Pubitemid 23318127)
43. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, et al,. (2007). Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148: 4965-4973. (Pubitemid 47481523)
44. Verspohl EJ, (2009). Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 124: 113-138.
45. Villanueva-Penacarrillo ML, Puente J, Redondo A, Clemente F, Valverde I, (2001). Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine 15: 241-248. (Pubitemid 32977337)
46. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, et al,. (2007). Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56: 1551-1558. (Pubitemid 46842610)
47. Yagihashi S, (1997). Nerve structural defects in diabetic neuropathy: do animals exhibit similar changes? Neurosci Res Commun 21: 25-32. (Pubitemid 27336349)
48. Yagihashi S, Kamijo M, Watanabe K, (1990). Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am J Pathol 136: 1365-1373. (Pubitemid 20210335)
49. Yu Z, Jin T, (2009). New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell Signal 22: 1-8.
50. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W, (2009). Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 247: 699-706.